Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial

Dae-Hyun Yoo,Chang-Hee Suh,Seung-Cheol Shim,Sławomir Jeka,Francisco Fidencio Cons-Molina,Paweł Hrycaj,Piotr Wiland,Eun Young Lee,Francisco G. Medina-Rodriguez,Pavel Shesternya,Sebastião Cezar Radominski,Marina Stanislav,Volodymyr Kovalenko,Dong Hyuk Sheen,Leysan Myasoutova,Mie Jin Lim,Jung-Yoon Choe,Sang Joon Lee,Sung-Young Lee,Sung-Hwan Kim,Won Park

Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial

2017

Background CT-P10 is a biosimilar of innovator rituximab (RTX), a biological therapy used to treat patients with rheumatoid arthritis (RA) who have responded inadequately to anti-tumor necrosis factor agents.

Keywords:

Biosimilar
Pharmacology
Rituximab
Randomized controlled trial
Rituximab Biosimilar CT-P10
Rheumatoid arthritis
Innovator
Medicine
Pharmacokinetics
Biosimilar Pharmaceuticals
Pharmacotherapy
Antirheumatic Agents

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations